Industrializing AI-powered drug discovery: lessons learned from the computing platform.

Journal: Expert opinion on drug discovery
Published Date: Jul 10, 2022

Abstract

INTRODUCTION: As a mid-size international pharmaceutical company, we initiated 4 years ago the launch of a dedicated high-throughput computing platform supporting drug discovery. The platform named ' was built up on the initial predicate to capitalize on our proprietary data while leveraging public data sources in order to foster a Computational Precision Medicine approach with the power of artificial intelligence.

Authors

  • Mickaël Guedj
    Servier, Research and Development, 50 rue Carnot, 92284 Suresnes Cedex, France.
  • Jack Swindle
    Lincoln, Research & Development, Boulogne-Billancourt, France.
  • Antoine Hamon
    Lincoln, Research & Development, Boulogne-Billancourt, France.
  • Sandra Hubert
    Servier, Research & Development, Suresnes, France.
  • Emiko Desvaux
    Servier, Research & Development, Suresnes, France.
  • Jessica Laplume
    Servier, Research & Development, Suresnes, France.
  • Laura Xuereb
    Servier, Research & Development, Suresnes, France.
  • Céline Lefebvre
    Servier, Research & Development, Suresnes, France.
  • Yannick Haudry
    Servier, Research & Development, Suresnes, France.
  • Christine Gabarroca
    Servier, Research and Development, 50 rue Carnot, 92284, Suresnes Cedex, France.
  • Audrey Aussy
    Servier, Research & Development, Suresnes, France.
  • Laurence Laigle
    Servier, Research & Development, Suresnes, France.
  • Isabelle Dupin-Roger
    Servier, Research & Development, Suresnes, France.
  • Philippe Moingeon
    Servier, Research and Development, 50 rue Carnot, 92284 Suresnes Cedex, France. Electronic address: philippe.moingeon@servier.com.

Keywords

External Resources

Popular Topics
Recent Journals